Archives: Speakers

Quinn leads her team in navigating Axiom’s clients throughout their entire project lifecycle based on their study needs, from Fusion eClinical Suite configuration to database lock and closeout activity. Quinn’s team is dedicated to executing well-planned processes to offer clients the best possible experience. Her passion lays with developing strategy, processes, and people as we continue to grow.

Dr. Patt is Co-Founder and Principal in RadMD. He has a broad prior experience in medical imaging: this includes research and development of contrast agents: design and manage site and central reviews and trained reviewers for over 300 oncology trials; and has expertise in cardiovascular device, infectious disease, and pulmonary fibrosis trials. He has performed blinded reads and adjudications in a variety of trial types. He has held positions as both an academic and private practice radiologist.

After his fellowship at Georgetown University and the National Institutes of Health (NIH), he served as Chief of Body MRI, then Director of MRI, at Georgetown University Medical Center, where he was both an investigator and blinded reader in numerous pharmaceutical and medical device clinical trials.

He subsequently joined Berlex Labs as Associate Director, followed by Director of Medical Imaging Clinical Development. where he managed an experienced team in all phases of clinical development of radiological contrast agents.

Dr. Patt also served as Medical Director for HealthHelp, a radiology management services organization. He founded Foresight Consulting, working with pharmaceutical and medical device companies on the utilization of medical imaging into clinical development programs.

He has numerous publications, has served on an NCI Advisory Panel, is a reviewer for major radiology journals, and has been an invited lecturer across the US and Europe on the use of medical imaging in clinical trials.

Oliver has more than 20 years of experience in pharmaceutical, diagnostics and medical technology solution. He joined in 2022 Roche to lead a regulatory team focusing on especially oncology companion diagnostics. Till end 2011 he was the Vice president Clinical and regulatory affairs in Imagion Biosystems, a FDA-Breakthrough status clinical stage medical device company combining transformative, high-sensitivity imaging and nanomedicine for better, safer diagnosis and therapy delivery in cancer and other diseases. Previously, Oliver served as Vice President R&D at TransCode Therapeutics, dedicated to microRNA-targeted, image-guided, personalized cancer detection and treatment solutions. Before, he held at PHILIPS the positions of Senior Director Clinical Research Board, governing the North America clincial innovation program, moving several products through human trials and approval, further as Senior Director Biomolecular Engineering leading diagnostic/interventional imaging and drug-device combination developments. Oliver started in various R&D positions at ALTANA Pharma AG building the Functional Genomics Group and entrepreneurial ALTANA Research Institute. He received his Ph. D. degree in biochemistry from the University of Tuebingen, Germany

John Spooner, head of Artificial Intelligence, EMEA, H2O.ai, leads the EMEA technical and data science teams, in advising organisations on democratising artificial intelligence and embedding it into their business decision-making.